Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of vortioxetine 20 mg tablet vs two 10 mg tablets in healthy adults
jRCT2080223807Phase 1Completed
- Sponsor
- Takeda
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vortioxetine in major depressive disorder (MDD) (2 arms), sponsored by Takeda. Primary endpoint: Primary pharmacokinetic endpoints. Started Feb 2018; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080223807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223807.